Heavy Menstrual Bleeding: Contraceptives
(asked on 11th November 2024) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of increasing access to long-acting reversible contraception for heavy menstrual bleeding in primary care on (a) waiting times and (b) demand for secondary care gynaecology services.
The National Institute for Health and Care Excellence’s guideline on heavy menstrual bleeding recommends an intrauterine system or hormonal coil, which is a form of long-acting reversible contraception (LARC), as a first line treatment. In the women’s health strategy call for evidence, held in 2021, we heard about the challenges women faced accessing LARCs for the management of menstrual problems.
A cost benefit analysis on women’s health hubs conducted by the Department estimated that if 50% of LARC procedures for gynaecology were provided in women’s health hubs, it would produce a net saving of £1.8 million, and reduce pressures on secondary care gynaecology services. The cost benefit analysis is available at the following link:
The Department is continuing to work with NHS England to support the establishment of at least one pilot women’s health hub in every integrated care system, following a £25 million investment. Pilot women’s health hubs provide intermediate and streamlined care in the community, which reduces pressures on services such as secondary care referrals and general practice appointments. A core service offered by hubs is treatment for heavy menstrual bleeding, and the fitting or removal of a LARC. Cutting waiting lists, including for gynaecology, is a key part of our Health Mission and a top priority for the Government.